托伐普坦在高龄心力衰竭患者中的应用效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application effect of Tolvaptan in the treatment of heart failure in elderly patients.Methods From September 2017 to September 2020, 80 elderly patients with heart failure admitted to Hongshan District Hospital of Traditional Chinese Medicine in Wuhan City were selected as the research objects, and the patients were divided into the observation group (40 cases) and the control group (40 cases) by random number table method. Patients in the control group were given conventional anti-heart failure treatment, and the observation group was given Tolvaptan on the basis of the control group. The recovery of heart function, related laboratory indicators and 24-hour urine output between the two groups of patients before and after treatment were compared. Results After treatment, the left ventricular ejection fraction (LVEF) of the observation group was higher than that of the control group, while the left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), and heart rate (HR) of the observation group were lower than those of the control group, the differences were statistically significant (P＜0.05). After treatment, the levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and serum galectin (Gal-3) of the observation group were lower than those of the control group, and the serum sodium ion (Na+) concentration, the 24-hour urine output of the observation group were higher than those of the control group, the differences were statistically significant (P＜0.05). There was no statistical difference in the serum potassium ion (K+) concentration between the two groups after treatment (P＞0.05). Conclusion Tolvaptan can significantly improve the heart function of patients with heart failure, promote the increase of urine output and blood sodium concentration in patients, and the effect is significant.

Key words： Tolvaptan Advanced age Heart failure Clinical effect

Received: 13 January 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHENG Su

Cite this article:

CHENG Su. Application effect of Tolvaptan in elderly patients with heart failure[J]. 中国当代医药, 2021, 28(19): 89-92.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I19/89

[1]	王毅，杨征.托伐普坦和沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能及血清钠水平的影响研究[J].陕西医学杂志，2019，48（4）：470-472.
[2]	王海燕，姜卫星，田丽，等.沙库巴曲缬沙坦对急性前壁ST段抬高型心肌梗死PCI 术后心力衰竭患者心功能的影响[J].河北医科大学学报，2020，41（3）：254-258，267.
[3]	易善婷，陈琳琳，王小芳，等.托伐普坦治疗急性充血性心力衰竭合并慢性肾功能不全的临床疗效研究[J].中国现代医学杂志，2020，30（11）：92-97.
[4]	黄琨，马威，郑川燕，等.托伐普坦治疗老年难治性心力衰竭的效果及对神经内分泌因子的影响[J].中国老年学杂志，2018，38（5）：1025-1028.
[5]	熊雪，钟燕，余瑷砾，等.托伐普坦对不同射血分数慢性心衰患者的临床疗效[J].心血管康复医学杂志，2020，29（2）：174-178.
[6]	徐宝华，赵刚.托伐普坦治疗急性心肌梗死合并心力衰竭的疗效及对心肾功能的影响[J].中国老年学杂志，2018，38（15）：3625-3627.
[7]	赵勇，沈彬，张建国，等.慢性心衰合并肾功能不全患者长期应用托伐普坦的疗效[J].心血管康复医学杂志，2020，29（3）：332-335.
[8]	刘静，李家富，邹立力，等.服用托伐普坦治疗引起的血浆渗透压升高对慢性心力衰竭患者预后的影响研究[J].中国全科医学，2019，22（2）：151-156.
[9]	郭慧.托伐普坦应用于慢性心衰治疗中的临床观察[J].中国处方药，2020，18（12）：90-92.
[10]	张博，赵萍，许杰，等.托伐普坦联合新活素与联合米力农治疗顽固性心力衰竭疗效对比[J].中华保健医学杂志，2020，22（1）：23-25.
[11]	张小兰，贺新荣，李文波，等.托伐普坦对老年心力衰竭患者心功能和神经内分泌因子的影响[J].中华老年多器官疾病杂志，2019，18（12）：918-922.
[12]	刘美林，高宇勤，张一凡，等.沙库巴曲缬沙坦联合托伐普坦治疗慢性心力衰竭的疗效观察[J].检验医学与临床，2020，17（21）：3144-3147.
[13]	程小航，张宸，刘善伟，等.托伐普坦在心力衰竭治疗的研究进展[J].中国循证心血管医学杂志，2018，10（11）：1436-1438.
[14]	成小丽，马淑梅.托伐普坦在心衰合低钠血症老年患者中的疗效评价[J].实用药物与临床杂志，2017，20（6）：653-656.
[15]	王伟，边瓯，马宁，等.小剂量托伐普坦联合呋塞米治疗急性心力衰竭合并利尿剂抵抗超高龄老年患者临床评价[J].临床军医杂志，2016，44（6）：601-604.